Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Opioid Clinical Efficacy Standards Need Rethinking, FDA Panel Says

Executive Summary

Outcomes measures should go beyond self-reported pain scores to include effects on function and quality of life, advisory committee members said during review of Teva's long-acting opioid Vantrela.


Related Content

Opioid Policy At US FDA: Gottlieb Seeks More Activist Role To Combat Abuse
Opioid Approval Standards Not Up For Debate, FDA Tells Advisory Cmte.
Egalet's Arymo ER Opioid Has Questionable Oral Abuse-Deterrent Effect
Marketing Value Of Abuse-Deterrent Labeling Weighed At Vantrela Review


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts